GlassScriptPhysician profile
Anton Dragonetti
NPI 1972091221
$4,116.39
in general payments reported to CMS, 2019-2025
19 companies · $839 in 2025
The $839 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $367 · 2022: $670 · 2023: $1,873 · 2024: $367 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.52 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,092.72 | 2021-2025 | Ingrezza |
| Abbvie INC. | $519.93 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $405.70 | 2022-2023 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $343.38 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $335.71 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $256.66 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $247.35 | 2022-2023 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Idorsia Pharmaceuticals US INC | $227.40 | 2022-2023 | Quviviq |
| Corium, LLC | $163.58 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $114.41 | 2022-2023 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $113.67 | 2023-2025 | Aplenzin |
| Neos Therapeutics, LP | $81.66 | 2025 | Adzenys Xr-Odt, Exxua |
| E.R. Squibb & Sons, L.L.C. | $47.97 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $47.66 | 2023-2024 | Auvelity |
| Merck Sharp & Dohme LLC | $34.77 | 2022-2023 | Belsomra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $28.64 | 2021 | |
| Sunovion Pharmaceuticals INC. | $24.99 | 2022 | |
| Almatica Pharma LLC | $15.96 | 2022 | |
| Indivior INC. | $14.23 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Dragonetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.